TrialThe Lancet. Infectious diseases2021

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.

Keith J Chappell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.